Telik, Inc.  

(Public, NASDAQ:TELK)   Watch this stock  
Find more results for TELK
Jul 10 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.05 - 2.15
Open     -
Vol / Avg. 0.00/33,921.00
Mkt cap 6.69M
P/E     -
Div/yield     -
EPS -0.95
Shares 4.58M
Beta 0.10
Inst. own 5%

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -204.28% -126.97%
Return on average equity -381.96% -221.75%
Employees 22 -
CDP Score - -


United States - Map
+1-650-8457700 (Phone)
+1-650-8457800 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company´┐Żs drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In July 2014, Telik Inc announced that MabVax Therapeutics merged with a wholly owned subsidiary of Telik Inc and became a wholly owned subsidiary of Telik Inc.

Officers and directors

Michael M. Wick M.D., Ph.D. Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
J. David Hansen President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Gregory P. Hanson Chief Financial Officer
Bio & Compensation  - Reuters
Wendy K. Wee Principal Accounting Officer, Vice President - Finance, Controller
Age: 60
Bio & Compensation  - Reuters
Philip O. Livingston M.D. Chief Science Officer, Director
Bio & Compensation  - Reuters
William P. Kaplan Esq. Vice President, General Counsel, Corporate Secretary, Vice President - Legal Affairs
Age: 59
Bio & Compensation  - Reuters
Wolfgang W. Scholz Ph.D Vice President - Antibody Discovery
Bio & Compensation  - Reuters
Steven R. Schow Ph.D. Vice President - Research
Age: 63
Bio & Compensation  - Reuters
Jim J. Antonopoulos Director
Bio & Compensation  - Reuters
Kenneth M. Cohen Director
Age: 59
Bio & Compensation  - Reuters